Market Currents
Impax Laboratories (IPXL +1%) says the FDA has extended its review of the company's new drug...
-
Friday, October 12, 2012, 3:15 PM ETImpax Laboratories (IPXL +1%) says the FDA has extended its review of the company's new drug application for Rytary, a potential treatment for Parkinson's disease, until January. The agency notes that IPXL had submitted additonal requested information late last month, for which it still needs time to review.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
